1
|
Zong H, Zhou H, Xiang Y, Wu G. miR-125b suppresses cellular proliferation by targeting c-FLIP in gallbladder carcinoma. Oncol Lett 2019; 18:6822-6828. [PMID: 31788125 DOI: 10.3892/ol.2019.11000] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Accepted: 08/13/2019] [Indexed: 01/07/2023] Open
Abstract
Gallbladder carcinoma (GBC) is the most common malignant tumor of the biliary tract. The incidence rate of gallbladder cancer ranks sixth among gastrointestinal types of cancer, and its incidence is increasing each year. Further clarification of the pathogenesis of GBC is essential, and identification of novel effective treatments is required. It has been previously demonstrated that high expression of the anti-apoptotic protein cellular Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein (c-FLIP) in GBC inhibited apoptosis in gallbladder cancer cells. In subsequent experiments, it was observed that microRNA (miR)-125b could target c-FLIP and inhibit the protein expression of c-FLIP by binding to the 3'untranslated regions of c-FLIP mRNA. In addition, the expression of miR-125b in GBC was significantly decreased, and the growth of gallbladder cancer cells was inhibited by the overexpression of miR-125b. The present study demonstrated that miR-125b could suppress the proliferation of gallbladder cancer cells by targeting c-FLIP. c-FLIP enriched the target gene pathway of miR-125b and may serve as a novel target for the treatment of GBC.
Collapse
Affiliation(s)
- Huajie Zong
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
| | - Huading Zhou
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
| | - Yang Xiang
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
| | - Gang Wu
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
| |
Collapse
|
2
|
Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. J Clin Oncol 2009; 27:4413-21. [DOI: 10.1200/jco.2008.21.7422] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose A phase I study assessed the safety, tolerability, pharmacokinetics, and preliminary antitumor effect of mapatumumab, a fully-human agonist monoclonal antibody to the tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1, DR4), in combination with paclitaxel and carboplatin. Patients and Methods Patients with advanced solid malignancies received 3, 10, or 20 mg/kg of mapatumumab with standard doses of paclitaxel and carboplatin every 21 days for up to six cycles in the absence of disease progression. Additional cycles of paclitaxel and/or mapatumumab were permissible in selected cases. Results Twenty-seven patients (21 males), with a median age of 54 years, received mapatumumab in the following three cohorts: 3 mg/kg (n = 4), 10 mg/kg (n = 11), and 20 mg/kg (n = 12). The median number of cycles was four. Dose-limiting toxicities (DLTs) were grade 3 hypersensitivity reaction (n = 1) and neutropenic fever (n = 1), both at 10 mg/kg. Non-DLT treatment-related adverse events occurring in more than 10% of administered doses included alopecia, neutropenia, fatigue, nausea, anemia, thrombocytopenia, anorexia, and neuropathy. Paclitaxel and carboplatin exposures were similar in the presence or absence of mapatumumab. Plasma mapatumumab concentrations seemed similar to data from previous phase I monotherapy studies. Five patients (19%) achieved a confirmed radiologic partial response (including one pathologic complete response), and 12 patients (44%) had stable disease as their best response. Conclusion Mapatumumab is well-tolerated up to 20 mg/kg in combination with paclitaxel and carboplatin. There are no apparent pharmacokinetic interactions among the drugs. Preliminary anticancer activity demonstrated clinical benefit for the majority of these patients.
Collapse
Affiliation(s)
- Stephen Leong
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Roger B. Cohen
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Daniel L. Gustafson
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Corey J. Langer
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - D. Ross Camidge
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Kristin Padavic
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Lia Gore
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Margaret Smith
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Laura Q. Chow
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Margaret von Mehren
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Cindy O'Bryant
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Sujatha Hariharan
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Sami Diab
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Norma Lynn Fox
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - Renée Miceli
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| | - S. Gail Eckhardt
- From the University of Colorado Health Sciences Center, Aurora, CO; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD
| |
Collapse
|